SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®

[January 21, 2014]

Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®

SAN DIEGO --(Business Wire)--

Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH). The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing (NGS) and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

Under the terms of the agreement, LabCorp will be able to purchase a broader range of Illumina products for the development of new diagnostic tools in multiple specialties, including genetic testing, oncology, transplant medicine and forensics, in addition to other applications. LabCorp is currently using the technology in connection with new human leukocyte antigen (HLA) tests that it plans to introduce this year.

"The Illumina next-generation sequencing platform gives LabCorp the flexibility to develop a wide range of molecular tests," said Dr. Mark Brecher, LabCorp's Chief Medical Officer. "The HLA typing assays we are developing on Illumina's family of NG platforms will provide physicians with the ability to more accurately match bone marrow donors to recipients."


"We are excited to support LabCorp's ability to offer more NGS-based tests such as its HLA offering," said Nicholas J. Naclerio, Illumina's Senior Vice President of Corporate & Venture Development. "Illumina is committed to making NGS broadly available for clinical laboratory testing, and this agreement with LabCorp significantly expands the number of clinicians and patients who will have access to improved diagnostic tools and information."

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy